Fortnightly Review: A rational approach to the management of hepatitis C infection
- 10 February 1996
- Vol. 312 (7027) , 357-364
- https://doi.org/10.1136/bmj.312.7027.357
Abstract
Summary points The natural course of chronic hepatitis C is not fully defined A range of disease exists—from mild asymptomatic infection with few consequences to serious disease with dire sequelae Pretreatment assessments of viral load and genotype or serotype may help in predicting response It is difficult to indicate the prognosis for younger patients with mild disease; they may need to be considered for treatment, so that the opportunity to avoid later disease is not forfeited It is not yet clear whether patients who are more responsive to interferon have a better prognosisKeywords
This publication has 46 references indexed in Scilit:
- Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled studyJournal of Hepatology, 1996
- Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patientsJournal of Hepatology, 1996
- Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyteJournal of Hepatology, 1995
- The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis: A 12-month double-blind, placebo-controlled trialJournal of Hepatology, 1994
- Response to interferon α therapy is influenced by the iron content of the liverJournal of Hepatology, 1994
- Sequence variability of hepatitis C virus and its clinical relevanceJournal of Viral Hepatitis, 1994
- Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis CThe Journal of Pediatrics, 1994
- Quantitative HCV RNA and effect of interferon therapy in chronic hepatitis CDigestive Diseases and Sciences, 1992
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989